Collaborative Arrangements and Licensing Agreements (Tables)

3 Months Ended

Mar. 31, 2024

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three months ended March 31, 2024 and 2023, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):

	Three Months Ended March 31,
	2024			2023
Revenue from our relationship with AstraZeneca	$	11,685		$	24,425
Percentage of total revenue		10	%		19	%

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three months ended March 31, 2024 and 2023, we earned the following revenue from our relationship with Biogen (in thousands, except percentage amounts):

	Three Months Ended March 31,
	2024			2023
Revenue from our relationship with Biogen	$	59,236		$	70,501
Percentage of total revenue		50	%		54	%